In the study, the research team presented
a novel pharmacologic candidate that alleviates age - related degenerative joint conditions, such as osteoarthritis (OA) by selectively destroying SnCs.
High profits may be justified if
novel products offer significant benefits to patients (thus producing indirect economic value through the patients» restored health) or if they represent significant
pharmacologic advances over their predecessors — offering new mechanisms of actions and emblematic of high - risk research.